The Patent Finder

Terms ending in 2041

Acceleron Pharma Inc.

Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,364,736Methods for Treating Heterotopic Ossification
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 12,583,906Actrii Proteins and Use in Treating Post-Capillary Pulmonary Hypertension
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 11,976,111Actriia and ALK4 Polypeptides for Treating Kidney Fibrosis, Inflammation and Injury
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited